Pure red cell aplasia: Difference between revisions
No edit summary |
No edit summary |
||
Line 21: | Line 21: | ||
==Overview== | ==Overview== | ||
Pure red cell aplasia was first discovered by Paul Kaznelson in 1922. Pure red cell aplasia may be classified into primary (idiopathic) PRCA and acquired red cell aplasia. It is thought that acquired pure red cell aplasia is the result of profound anemia due to severe reduction in number of RBC in peripheral blood and absence of erythroid precursors, proerythroblast in the bone marrow. Causes include autoimmune disease, thymoma, viral infections | |||
==Historical Perspective== | ==Historical Perspective== | ||
Line 28: | Line 29: | ||
==Classification== | ==Classification== | ||
There is no established system for the classification of pure red cell aplasia (PRCA). However it may be classified into primary (idiopathic) PRCA and acquired red cell aplasia. Diamond-Blackfan anemia (DBA) is a congenital form of red cell aplasia. | There is no established system for the classification of pure red cell aplasia (PRCA). However it may be classified into primary (idiopathic) PRCA and acquired red cell aplasia. Diamond-Blackfan anemia (DBA) is a congenital form of red cell aplasia. Based on the duration of symptoms, pure red cell aplasia may be classified as either acute or chronic. | ||
==Pathophysiology== | ==Pathophysiology== | ||
Line 78: | Line 79: | ||
The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click [[Pericarditis causes#Overview|here]]. | The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click [[Pericarditis causes#Overview|here]]. | ||
==Differentiating | ==Differentiating Pure Red Cell Aplasia from Other Diseases== | ||
Pure red cell aplasia must be differentiated from Transient erythroblastopenia of childhood, Diamond-Blackfan anemia (DBA) and Aplastic anemia. | Pure red cell aplasia must be differentiated from Transient erythroblastopenia of childhood, Diamond-Blackfan anemia (DBA) and Aplastic anemia. | ||
* Transient erythroblastopenia of childhood: Itr is self-limited condition during first years of life. | * Transient erythroblastopenia of childhood: Itr is self-limited condition during first years of life. | ||
Line 87: | Line 88: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* The incidence of Diamond-Blackfan anemia (DBA) is approximately 6.6 per 100,000 individuals in Erope. Pure red cell aplasia due to Diamond-Blackfan anemia (DBA)affects men and women equally and there is no racial predilection to this disease. | * The incidence of Diamond-Blackfan anemia (DBA) is approximately 6.6 per 100,000 individuals in Erope. Pure red cell aplasia due to Diamond-Blackfan anemia (DBA)affects men and women equally and there is no racial predilection to this disease. | ||
* The acquired form of pure red cell aplasia can presents as an acute self-limited disease predominantly in children or chronic illness that is more seen in adults.<ref name="pmid185106824">{{cite journal |vauthors=Sawada K, Fujishima N, Hirokawa M |title=Acquired pure red cell aplasia: updated review of treatment |journal=Br. J. Haematol. |volume=142 |issue=4 |pages=505–14 |date=August 2008 |pmid=18510682 |pmc=2592349 |doi=10.1111/j.1365-2141.2008.07216.x |url=}}</ref> | |||
* The incidence of thymoma in patients with pure red cell aplasia is about 5%. <ref name="pmid65818393">{{cite journal |vauthors=Clark DA, Dessypris EN, Krantz SB |title=Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients |journal=Blood |volume=63 |issue=2 |pages=277–86 |date=February 1984 |pmid=6581839 |doi= |url=}}</ref> | * The incidence of thymoma in patients with pure red cell aplasia is about 5%. <ref name="pmid65818393">{{cite journal |vauthors=Clark DA, Dessypris EN, Krantz SB |title=Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients |journal=Blood |volume=63 |issue=2 |pages=277–86 |date=February 1984 |pmid=6581839 |doi= |url=}}</ref> | ||
Line 106: | Line 108: | ||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic Study of Choice=== | ===Diagnostic Study of Choice=== | ||
* Complete blood count, peripheral smear, reticulocyte count | * Complete blood count, peripheral smear, reticulocyte count<ref name="pmid185106825">{{cite journal |vauthors=Sawada K, Fujishima N, Hirokawa M |title=Acquired pure red cell aplasia: updated review of treatment |journal=Br. J. Haematol. |volume=142 |issue=4 |pages=505–14 |date=August 2008 |pmid=18510682 |pmc=2592349 |doi=10.1111/j.1365-2141.2008.07216.x |url=}}</ref> | ||
* Hepatic function test | * Hepatic function test | ||
* Renal function test | * Renal function test | ||
Line 112: | Line 114: | ||
===History and Symptoms=== | ===History and Symptoms=== | ||
Common symptoms of pure red cell aplasia include fatigue and lethargy. | |||
===Physical Examination=== | ===Physical Examination=== | ||
Line 178: | Line 176: | ||
===Surgery=== | ===Surgery=== | ||
Surgery is usually reserved for patients with thymoma. <ref name="pmid65818394">{{cite journal |vauthors=Clark DA, Dessypris EN, Krantz SB |title=Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients |journal=Blood |volume=63 |issue=2 |pages=277–86 |date=February 1984 |pmid=6581839 |doi= |url=}}</ref> | Thymectomy: Surgery is usually reserved for patients with thymoma. <ref name="pmid65818394">{{cite journal |vauthors=Clark DA, Dessypris EN, Krantz SB |title=Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients |journal=Blood |volume=63 |issue=2 |pages=277–86 |date=February 1984 |pmid=6581839 |doi= |url=}}</ref> | ||
===Primary Prevention=== | ===Primary Prevention=== | ||
Line 194: | Line 192: | ||
<nowiki>}}</nowiki> | <nowiki>}}</nowiki> | ||
{{SI}} | {{SI}} | ||
{{CMG}}{{MA}} [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] | {{CMG}}{{MA}} [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] | ||
{{SK}} Acquired pure megakaryocytic aplasia, pure red cell aplasia, erythroblastopenia | {{SK}} Acquired pure megakaryocytic aplasia, pure red cell aplasia, erythroblastopenia |
Revision as of 20:24, 11 September 2018
Template:DiseaseDisorder infobox
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]
Synonyms and keywords: Acquired pure megakaryocytic aplasia, pure red cell aplasia, erythroblastopenia
Overview
Pure red cell aplasia was first discovered by Paul Kaznelson in 1922. Pure red cell aplasia may be classified into primary (idiopathic) PRCA and acquired red cell aplasia. It is thought that acquired pure red cell aplasia is the result of profound anemia due to severe reduction in number of RBC in peripheral blood and absence of erythroid precursors, proerythroblast in the bone marrow. Causes include autoimmune disease, thymoma, viral infections
Historical Perspective
Pure red cell aplasia was first discovered by Paul Kaznelson in 1922.[1]
A congenital form of PRCA was described by Diamond and Blackfan in 1938.
Classification
There is no established system for the classification of pure red cell aplasia (PRCA). However it may be classified into primary (idiopathic) PRCA and acquired red cell aplasia. Diamond-Blackfan anemia (DBA) is a congenital form of red cell aplasia. Based on the duration of symptoms, pure red cell aplasia may be classified as either acute or chronic.
Pathophysiology
It is thought that acquired pure red cell aplasia is the result of profound anemia due to severe reduction in number of RBC in peripheral blood and absence of erythroid precursors, proerythroblast in the bone marrow.The numbers of white blood cells and platelets are normal.[2].In autoimmune disorders, IgG fraction in serum inhibit the growth of normal erythroid progenitors. [3] In some cases of autoimmune PRCA, T lymphocytes suppress erythropoiesis. [4]
Causes
- Autoimmune disease
- Autoimmune hemolytic anemia
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Thymoma[5]
- Viral infections
- Lymphoproliferative disorders
- T-cell large granular lymphocyte leukemia, especially in china [8]
- Chronic lymphocytic leukemia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Myeloid malignancies such as Chronic myeloid leukemia
- Myelodysplastic syndrome[9]
- Idiopathic[10]
- Drugs [11][12][13]
- Phenytoin
- Chloramphenicol
- Azathioprine
- Isoniazid
- Valproic acid
- Erythropoietin
- Trimethoprim-sulfamethoxazole
- Zidovudine
- Chlorpropamide
- ABO- incompatible hematopoietic cell transplantation
- Anti- erythropoietin antibodies due to treatment with recombinant human erythropoietin[14]
- Plasma cell disorders[15]
- Pregnancy
The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.
Differentiating Pure Red Cell Aplasia from Other Diseases
Pure red cell aplasia must be differentiated from Transient erythroblastopenia of childhood, Diamond-Blackfan anemia (DBA) and Aplastic anemia.
- Transient erythroblastopenia of childhood: Itr is self-limited condition during first years of life.
- Diamond-Blackfan anemia (DBA): congenital form of red cell aplasia. It is associated with some malignancies and it does not respond to prednisone.
- Aplastic anemia: It affects other bone marrow cells as well.
Epidemiology and Demographics
- The incidence of Diamond-Blackfan anemia (DBA) is approximately 6.6 per 100,000 individuals in Erope. Pure red cell aplasia due to Diamond-Blackfan anemia (DBA)affects men and women equally and there is no racial predilection to this disease.
- The acquired form of pure red cell aplasia can presents as an acute self-limited disease predominantly in children or chronic illness that is more seen in adults.[16]
- The incidence of thymoma in patients with pure red cell aplasia is about 5%. [17]
Risk Factors
Common risk factors in the development of pure red cell aplasia include strong family history.
Screening
There is insufficient evidence to recommend routine screening for pure red cell aplasia.
Natural History, Complications, and Prognosis
If left untreated, 14% of patients with pure red cell aplasia may have spontaneously remitting disease.[18]
Pure red cell aplasia due to parvovirus infection usually resolve within 2-3 weeks. [19]
Common complications of pure red cell aplasia include infection due to side effects of some treatments such as glucocorticoids and cyclophosphamide.
Prognosis is generally good. In one study in 1984, survival in idiopathic pure red cell aplasia was more than 10 years, but only four years in pure red cell aplasia secondary to leukemia and lymphoma. [20]
Diagnosis
Diagnostic Study of Choice
- Complete blood count, peripheral smear, reticulocyte count[21]
- Hepatic function test
- Renal function test
- Bone marrow aspiration and biopsy
History and Symptoms
Common symptoms of pure red cell aplasia include fatigue and lethargy.
Physical Examination
Common physical examination findings of pure red cell aplasia include fast heart beat and pale apperance.
Laboratory Findings
Laboratory findings consistent with the diagnosis of pure red cell aplasia include:[22]
- Normocytic, normochromic anemia; rarely, macrocytic anemia may be seen.
- Very low or zero reticulocyte percentage and an absolute reticulocyte count <10,000/microL
- Normal white blood cell
- Normal platelet counts
- Bone marrow bipsy: normal myelopoiesis, lymphopoiesis, and megakaryocytopoiesis, but few erythroid precursors
Electrocardiogram
There are no ECG findings associated with pure red cell aplasia
X-ray
An x-ray may be helpful in the diagnosis of thymoma and other neoplasms.
Echocardiography or Ultrasound
There are no echocardiography/ultrasound findings associated with pure red cell aplasia.
CT scan
Chest CT scan may be helpful in the diagnosis of thymoma and other neoplasms. .
MRI
Chest MRI may be helpful in the diagnosis of thymoma and other neoplasms.
Imaging Findings
There are no other imaging findings associated with pure red cell aplasia.
Other Diagnostic Studies
- Viral studies for hepatitis c and parvovirus B19
- Autoimmune antibody studies
- karyotype
- T cell receptor clonality studies
- Peripheral blood immunophenotyping
Treatment
Medical Therapy
- Symptomatic anemia: Red blood cell transfusions
- Cessation of offending drugs
- Investigation for associated condition
- Pure red cell aplasia due to ABO incompatible hematopoietic cell transplantation is usually self limited.
- Intravenous immune globulin (IVIG): single infusion 400 mg/kg over 2-3 hours if spontaneous resolution does not occur during 2-3 weeks. [23] IVIG, 400 mg/kg daily for five day can be considered in resistant pure red cell aplasia. [24]
- Immunosuppressive therapy in idiopathic pure red cell aplasia such as: [25]
- Glucocorticoids: Prednisone, oral dose ( 60 mg/day in divided doses ). It is considerd as a initial treatment. [26]
- Glucocorticoids plus cyclosporine: If no response to glucocorticoids occur after one to two months. Cyclosporine oral dosage can be considered 200 to 600 mg/day.[27]
- Glucocorticoids plus cyclophosphamide: Cyclophosphamide oral dosage can be considered 2 to 3 mg/kg per day. [28]
- Refractory cases:
Surgery
Thymectomy: Surgery is usually reserved for patients with thymoma. [33]
Primary Prevention
There are no established measures for the primary prevention of pure red cell aplasia
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
References
- ↑ Sawada K, Fujishima N, Hirokawa M (August 2008). "Acquired pure red cell aplasia: updated review of treatment". Br. J. Haematol. 142 (4): 505–14. doi:10.1111/j.1365-2141.2008.07216.x. PMC 2592349. PMID 18510682.
- ↑ Dessypris EN (October 1991). "The biology of pure red cell aplasia". Semin. Hematol. 28 (4): 275–84. PMID 1759168.
- ↑ Dessypris EN (October 1991). "The biology of pure red cell aplasia". Semin. Hematol. 28 (4): 275–84. PMID 1759168.
- ↑ Lacy MQ, Kurtin PJ, Tefferi A (April 1996). "Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities". Blood. 87 (7): 3000–6. PMID 8639922.
- ↑ Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K, Fujisawa S, Yonemura Y, Kawano F, Omine M, Ozawa K (January 2008). "Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group". Haematologica. 93 (1): 27–33. doi:10.3324/haematol.11655. PMID 18166782.
- ↑ Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES (December 2000). "Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature". Clin Transplant. 14 (6): 586–91. PMID 11127313.
- ↑ al-Awami Y, Sears DA, Carrum G, Udden MM, Alter BP, Conlon CL (August 1997). "Pure red cell aplasia associated with hepatitis C infection". Am. J. Med. Sci. 314 (2): 113–7. PMID 9258213.
- ↑ Kwong YL, Wong KF (September 1998). "Association of pure red cell aplasia with T large granular lymphocyte leukaemia". J. Clin. Pathol. 51 (9): 672–5. PMC 500904. PMID 9930071.
- ↑ Dessypris EN (October 1991). "The biology of pure red cell aplasia". Semin. Hematol. 28 (4): 275–84. PMID 1759168.
- ↑ Miller AC, Rashid RM (2008). "Three episodes of acquired pure red cell aplasia restricted to pregnancy". J Perinat Med. 36 (3): 270–1. doi:10.1515/JPM.2008.041. PMID 18576941.
- ↑ Macdougall IC (November 2007). "Epoetin-induced pure red cell aplasia: diagnosis and treatment". Curr. Opin. Nephrol. Hypertens. 16 (6): 585–8. doi:10.1097/MNH.0b013e3282f0c4bf. PMID 18089975.
- ↑ Bartakke S, Abdelhaleem M, Carcao M (April 2008). "Valproate-induced pure red cell aplasia and megakaryocyte dysplasia". Br. J. Haematol. 141 (2): 133. doi:10.1111/j.1365-2141.2008.06979.x. PMID 18353161.
- ↑ Thompson DF, Gales MA (1996). "Drug-induced pure red cell aplasia". Pharmacotherapy. 16 (6): 1002–8. PMID 8947971.
- ↑ Rossert J, Yue S, Smirnakis K, Mytych DT, Johnson L, Kouchakji E, Casadevall N (February 2014). "Risk of pure red cell aplasia in patients with hepatitis C receiving antiviral therapy and an erythropoiesis-stimulating agent". Clin. Gastroenterol. Hepatol. 12 (2): 341–5. doi:10.1016/j.cgh.2013.09.065. PMID 24120841.
- ↑ Korde N, Zhang Y, Loeliger K, Poon A, Simakova O, Zingone A, Costello R, Childs R, Noel P, Silver S, Kwok M, Mo C, Young N, Landgren O, Sloand E, Maric I (June 2016). "Monoclonal gammopathy-associated pure red cell aplasia". Br. J. Haematol. 173 (6): 876–83. doi:10.1111/bjh.14012. PMC 5549779. PMID 26999424.
- ↑ Sawada K, Fujishima N, Hirokawa M (August 2008). "Acquired pure red cell aplasia: updated review of treatment". Br. J. Haematol. 142 (4): 505–14. doi:10.1111/j.1365-2141.2008.07216.x. PMC 2592349. PMID 18510682.
- ↑ Clark DA, Dessypris EN, Krantz SB (February 1984). "Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients". Blood. 63 (2): 277–86. PMID 6581839.
- ↑ Clark DA, Dessypris EN, Krantz SB (February 1984). "Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients". Blood. 63 (2): 277–86. PMID 6581839.
- ↑ Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS (August 1989). "Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy". N. Engl. J. Med. 321 (8): 519–23. doi:10.1056/NEJM198908243210807. PMID 2548098.
- ↑ Clark DA, Dessypris EN, Krantz SB (February 1984). "Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients". Blood. 63 (2): 277–86. PMID 6581839.
- ↑ Sawada K, Fujishima N, Hirokawa M (August 2008). "Acquired pure red cell aplasia: updated review of treatment". Br. J. Haematol. 142 (4): 505–14. doi:10.1111/j.1365-2141.2008.07216.x. PMC 2592349. PMID 18510682.
- ↑ Sawada K, Fujishima N, Hirokawa M (August 2008). "Acquired pure red cell aplasia: updated review of treatment". Br. J. Haematol. 142 (4): 505–14. doi:10.1111/j.1365-2141.2008.07216.x. PMC 2592349. PMID 18510682.
- ↑ Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, Montagnier-Petrissans C, Guillevin L, Mouthon L (April 2013). "Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature". Clin. Infect. Dis. 56 (7): 968–77. doi:10.1093/cid/cis1046. PMID 23243178.
- ↑ Ballester OF, Saba HI, Moscinski LC, Nelson R, Foulis P (July 1992). "Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate". Semin. Hematol. 29 (3 Suppl 2): 106–8. PMID 1509289.
- ↑ Sawada K, Fujishima N, Hirokawa M (August 2008). "Acquired pure red cell aplasia: updated review of treatment". Br. J. Haematol. 142 (4): 505–14. doi:10.1111/j.1365-2141.2008.07216.x. PMC 2592349. PMID 18510682.
- ↑ Lacy MQ, Kurtin PJ, Tefferi A (April 1996). "Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities". Blood. 87 (7): 3000–6. PMID 8639922.
- ↑ Raghavachar A (1990). "Pure red cell aplasia: review of treatment and proposal for a treatment strategy". Blut. 61 (2–3): 47–51. PMID 1698487.
- ↑ Lacy MQ, Kurtin PJ, Tefferi A (April 1996). "Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities". Blood. 87 (7): 3000–6. PMID 8639922.
- ↑ Abkowitz JL, Powell JS, Nakamura JM, Kadin ME, Adamson JW (December 1986). "Pure red cell aplasia: response to therapy with anti-thymocyte globulin". Am. J. Hematol. 23 (4): 363–71. PMID 3098093.
- ↑ Ghazal H (February 2002). "Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia". Blood. 99 (3): 1092–4. PMID 11807020.
- ↑ Ru X, Liebman HA (October 2003). "Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H)". Br. J. Haematol. 123 (2): 278–81. PMID 14531909.
- ↑ Sloand EM, Scheinberg P, Maciejewski J, Young NS (February 2006). "Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab)". Ann. Intern. Med. 144 (3): 181–5. PMID 16461962.
- ↑ Clark DA, Dessypris EN, Krantz SB (February 1984). "Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients". Blood. 63 (2): 277–86. PMID 6581839.
}}
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]Mahda Alihashemi M.D. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36]
Synonyms and keywords: Acquired pure megakaryocytic aplasia, pure red cell aplasia, erythroblastopenia
Overview
Acquired pure red cell aplasia (or PRCA) refers to a type of anemia affecting the precursors to red blood cells but not to white blood cells. In PRCA, the bone marrow ceases to produce red blood cells.
Historical Perspective
Classification
Pathophysiology
Causes
Pure red cell aplasia is regarded as an autoimmune disease. It may also be a manifestation of thymoma. It may also be as a result of viral infections such as HIV, herpes, parvovirus B19 (Fifth disease), or hepatitis. Association of pure red cell aplasia with T large granular lymphocyte leukemia is also well recognized, especially in China (http://jcp.bmj.com/cgi/content/abstract/51/9/672). Many cases of PRCA are considered idiopathic in that there is no discernable cause detected.
It can be associated with the administration of erythropoietin.
Differentiating [Disease] from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Drug Side Effect
PRCA is considered an autoimmune disease as it will respond to immunosuppressant treatment such as ciclosporin. It has also been also been shown to respond to treatments with Rituxan.
Contraindicated medications
Pure red cell aplasia is considered an absolute contraindication to the use of the following medications:
Surgery
Prevention
See also
- Diamond-Blackfan anemia (genetic red cell aplasia)
- aplastic anemia (aplasia affecting other bone marrow cells as well)